HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.
Hanssen Pharma (03692) announced that its self-developed class 1 new drug HS-10582 tablets have received the clinical trial approval notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."
HANSOH PHARMA (03692) announced that its self-developed Class 1 new drug HS-10582 tablets have received a clinical trial approval notification from the National Medical Products Administration (NMPA) in China, aimed at conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."
Related Articles
Shanxi Coking Coal Energy Group (000983.SZ) has suspended production at the Xiqu Mine due to an accident.
WINNING TOWER (08362) expects a net profit of approximately HKD 1.9 million for the first half of the year.
Puya Semiconductor (Shanghai) Co., Ltd. (688766.SH) plans to launch a restricted stock incentive plan in 2026.
Shanxi Coking Coal Energy Group (000983.SZ) has suspended production at the Xiqu Mine due to an accident.
WINNING TOWER (08362) expects a net profit of approximately HKD 1.9 million for the first half of the year.
Puya Semiconductor (Shanghai) Co., Ltd. (688766.SH) plans to launch a restricted stock incentive plan in 2026.
RECOMMEND
